news-med.jpg

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Topics: Corporate, Evotec, Drug Discovery, CENTOGENE, rare genetic diseases, IPSC Read More

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity

The alliance builds upon Evotec's leading drug discovery and development capabilities in diabetes and related co-morbidities Novo Nordisk accesses Evotec's integrated discovery and development platform to progress new molecules from concept to IND including Evotec's INDiGO platform

Topics: Corporate, Evotec, Novo Nordisk, diabetes, Obesity, Drug Discovery, Drug Development Read More

Evotec’s Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact

THE £ 13 M DRUG DISCOVERY PARTNERSHIP BETWEEN OXFORD UNIVERSITY, OXFORD SCIENCES INNOVATION AND EVOTEC SUPPORTED 12 NEW PROJECTS IN FIRST YEAR OF OPERATION Hamburg, Germany, 11 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the £ 13 ...

Topics: Corporate, Drug Discovery Read More

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim

ACHIEVEMENT MARKS 24TH MILESTONE UNDER ALLIANCE TO DATE Hamburg, Germany, 01 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues ...

Topics: Business, Contract Reseach Organization, Corporate, Drug Discovery, Respiratory Read More

Evotec AG announces first nine-month 2017 results and corporate update

Strong operational and financial performance Expansion of leading external innovation platform through acquisition of aptuit Important milestone achievements and new ways of accelerating innovation Hamburg, Germany, 08 November 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ...

Topics: Corporate, Drug Discovery, Drug Development Read More

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”

Collaboration aimed at developing novel “Nephron-on-a Chip” device to test drug candidates in human kidney: NEPLEX (“Nephron-on-a-Chip with Cellular and Extracellular Matrix Complexity”) Major step forward to the next generation Kidney Platform Hamburg, Germany, 06 November 2017: Evotec AG ...

Topics: Corporate, Drug Discovery, Drug Development Read More

New Research by Cyprotex on Transporter DDI Published in Pharmacology Research & Perspectives

New research by Cyprotex in the field of metformin drug-drug interactions has been published in Pharmacology Research & Perspectives. The publication assists in further understanding the mechanism behind clinically observed DDIs with the common co-medication, metformin. Read our blog and download ...

Topics: Corporate, Drug Discovery, Drug Development Read More

Evotec and Tesaro Enter Strategic Partnership To Discover Novel Immuno-Oncology Agents

Discovery and development of inhibitors against Tesaro's Immuno-Oncology target utilising Evotec's comprehensive discovery and development platform Hamburg, Germany, 26 October 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a ...

Topics: Corporate, Drug Discovery, Drug Development Read More

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion ...

Topics: Corporate, Drug Discovery, Drug Development, Partner Research Organization Read More

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Topics: Corporate, Drug Discovery, Drug Development, Partner Research Organization Read More

Most Read

Posts by Topic